Hideyuki Yamawaki1, Bradford C Berk. 1. Center for Cardiovascular Research, Department of Medicine, University of Rochester, 601 Elmwood Avenue, Rochester, NY 14642, USA.
Abstract
PURPOSE OF REVIEW: Recent studies indicate that an imbalance in cell redox state alters multiple cell pathways that may contribute to the pathogenesis of cardiovascular disorders including hypertension and renal failure. RECENT FINDINGS: The thioredoxin system (thioredoxin, thioredoxin reductase, and NADPH) is a ubiquitous thiol oxidoreductase system that regulates cellular reduction/oxidation (redox) status. Thioredoxin plays an essential role in cell function by limiting oxidative stress directly via antioxidant effects and indirectly by protein-protein interactions with key signaling molecules such as thioredoxin-interacting protein (TXNIP). Examples include the findings that hyperglycemia and diabetes induce TXNIP and decrease thioredoxin activity, while steady blood flow decreases TXNIP and increases thioredoxin activity. SUMMARY: Based on these findings we propose that thioredoxin and its endogenous regulators represent important future targets to develop clinical therapies for diseases associated with oxidative stress.
PURPOSE OF REVIEW: Recent studies indicate that an imbalance in cell redox state alters multiple cell pathways that may contribute to the pathogenesis of cardiovascular disorders including hypertension and renal failure. RECENT FINDINGS: The thioredoxin system (thioredoxin, thioredoxin reductase, and NADPH) is a ubiquitous thiol oxidoreductase system that regulates cellular reduction/oxidation (redox) status. Thioredoxin plays an essential role in cell function by limiting oxidative stress directly via antioxidant effects and indirectly by protein-protein interactions with key signaling molecules such as thioredoxin-interacting protein (TXNIP). Examples include the findings that hyperglycemia and diabetes induce TXNIP and decrease thioredoxin activity, while steady blood flow decreases TXNIP and increases thioredoxin activity. SUMMARY: Based on these findings we propose that thioredoxin and its endogenous regulators represent important future targets to develop clinical therapies for diseases associated with oxidative stress.
Authors: Tali Zitman-Gal; Janice Green; Zeev Korzets; Jacques Bernheim; Sydney Benchetrit Journal: In Vitro Cell Dev Biol Anim Date: 2015-03-06 Impact factor: 2.416